Natixis Editas Medicine, Inc. Transaction History

Natixis

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$6.25 - $11.11 $753,806 - $1.34 Million	120,609 New	120,609 $1.22 Million
Q2 2023 Aug 11, 2023	SELL	$6.36 - $11.47 $273 - $493	-43 Reduced 1.61%	2,623 $21,000
Q4 2022 Feb 24, 2023	BUY	$8.32 - $13.21 $22,181 - $35,217	2,666 New	2,666 $23,000
Q2 2022 Aug 12, 2022	SELL	$9.99 - $21.35 $845,813 - $1.81 Million	-84,666 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$14.08 - $27.63 $1,788 - $3,509	-127 Reduced 0.15%	84,666 $1.61 Million
Q3 2021 Nov 12, 2021	SELL	$39.27 - $72.94 $328,532 - $610,216	-8,366 Reduced 8.98%	84,793 $3.48 Million
Q2 2021 Aug 13, 2021	SELL	$31.29 - $56.64 $335,679 - $607,633	-10,728 Reduced 10.33%	93,159 $5.28 Million
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $4.13 Million - $9.41 Million	103,887 New	103,887 $4.36 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.